Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.57 |
| ▸ | G6PD | P11413 | 5/20 | 0.56 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SHBG | P04278 | 2/20 | 0.55 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436613 | 1.00 | MAPK1 (0.74) | MAPK1ALDH1A1TP53MAPTHSD17B3 | |
| SCHEMBL14876820 | 1.00 | MAPK1 (0.74) | MAPK1ALDH1A1TP53MAPTHSD17B3 | |
| SCHEMBL10301246 | 1.00 | MAPK1 (0.74) | MAPK1ALDH1A1TP53MAPTHSD17B3 | |
| SCHEMBL2436612 | 1.00 | MAPK1 (0.74) | MAPK1ALDH1A1TP53MAPTHSD17B3 | |
| SCHEMBL2435125 | 1.00 | MAPK1 (0.74) | MAPK1ALDH1A1TP53MAPTHSD17B3 | |
| SCHEMBL16345488 | 1.00 | MAPK1 (0.74) | MAPK1ALDH1A1TP53MAPTHSD17B3 | |
| SCHEMBL8298983 | 0.91 | MAPK1 (0.72) | MAPK1ALDH1A1TP53MAPTHSD17B3 | |
| SCHEMBL17793605 | 0.87 | MAPK1 (0.56) | MAPK1ALDH1A1TP53MAPTHSD17B3 | |
| SCHEMBL16407333 | 0.87 | MAPK1 (0.56) | MAPK1ALDH1A1TP53MAPTHSD17B3 | |
| SCHEMBL7989713 | 0.85 | MAPK1 (1.00) | MAPK1ALDH1A1TP53MAPTHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3581563-B1 | SHIP INHIBITORS AND USES THEREOF | THE RESEARCH FOUNDATION OF THE STATE UNIV OF NEW YORK (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20220162254-A1 | SHIP INHIBITORS AND USES THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2022-05-26 | — | — | US | disclosed |
| US-11319336-B2 | Ship inhibitors and uses thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2022-05-03 | — | — | US | disclosed |
| US-20220023315-A1 | METHODS OF ACTIVATING MICROGLIAL CELLS | UNIV NEW YORK STATE RES FOUND (US) | 2022-01-27 | — | — | US | disclosed |
| US-20200376005-A1 | SHIP INHIBITION TO COMBAT OBESITY | The Research Foundation for the State of University of New York | 2020-12-03 | — | — | US | disclosed |
| EP-3695841-A2 | SHIP INHIBITION TO COMBAT OBESITY | The Research Foundation for the State University of New York (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3016660-B1 | SHIP INHIBITION TO COMBAT OBESITY | UNIV NEW YORK STATE RES FOUND (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-2556055-B1 | SHIP INHIBITORS AND USES THEREOF | THE RESEARCH FOUNDATION OF THE STATE UNIV OF NEW YORK (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20170051006-A1 | SHIP INHIBITORS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-02-23 | — | — | US | disclosed |
| US-9447139-B2 | Ship inhibitors and uses thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2016-09-20 | — | — | US | disclosed |
| WO-2011109704-A1 | ANTIMICROBIAL CATIONIC STEREOIDS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2010062562-A1 | SYNTHESIS AND USE OF CATIONIC STEROIDS FOR ANTI-INFLAMMATORY DRUG THERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20090124591-A1 | Synthesis and Use of Cationic Steroids for Anti-Inflammatory Drug Therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2009-05-14 | — | — | US | disclosed |
| US-7442386-B2 | Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1424998-A4 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | UNIV PENNSYLVANIA (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050069577-A1 | Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies | TRUSTEES OF UNIVERSITY OF PENNSYLVANIA | 2005-03-31 | — | — | US | disclosed |
| EP-1424998-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | The Trustees of The University of Pennsylvania (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003015757-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200376005-A1 | SHIP INHIBITION TO COMBAT OBESITY | PPM1G, PPM1B, PPM1F | MAPK1 1001/4885ALDH1A1 2869/4885TP53 4864/4885 |
| US-11319336-B2 | Ship inhibitors and uses thereof | PPP5C, DUSP1, DUSP5 | MAPK1 1533/4885ALDH1A1 1788/4885TP53 1209/4885 |
| US-20220023315-A1 | METHODS OF ACTIVATING MICROGLIAL CELLS | LPCAT3, PLAAT2, PLA2G4B | MAPK1 3303/4885ALDH1A1 3288/4885TP53 4361/4885 |
| US-20220162254-A1 | SHIP INHIBITORS AND USES THEREOF | PPP5C, DUSP1, DUSP5 | MAPK1 1533/4885ALDH1A1 1788/4885TP53 1209/4885 |
| US-20170051006-A1 | SHIP INHIBITORS AND USES THEREOF | PPP5C, DUSP1, DUSP5 | MAPK1 1533/4885ALDH1A1 1788/4885TP53 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.